Cognito is a clinical-stage company developing novel digital therapeutics with a proprietary neuromodulation platform which holds the promise for disease-modification in neurodegenerative diseases such as Alzheimer’s.
STALICLA is a Swiss clinical stage biotech company deploying and applying a first in class discovery platform to bring precision medicine to patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).
STALICLA has assembled a world-class team of 26 seasoned drug developers, clinicians, data scientists and computational biologists.
DEPI, the company's NDD precision medicine platform leveraging on ML and transcriptomics technology, has reached proof of concept for its capacity to characterize biologically similar subgroups of patients within highly variable populations of patients with neurodevelopmental disorders, and to further identify tailored treatment candidates.
To further advance its drug discovery platform and pipeline, STALICLA has established strong networks within top tier research and clinical centers in the United States and Europe.
STALICLA currently has one precision medicine candidate in the clinic and plans to bring two assets into Phase 2 in 2022.
The company is also advancing collaborative alliances with strategic third party pipelines.
STALICLA has raised UDS 27M to date and is rapidly scaling its platform and clinical development activity. For more information, please visit company's website.
Zeto is a medical technology startup democratizing EEG (Electroencephalography) for healthcare. We are solving a problem unsolved for over 90 years, an archaic, tedious approach that consumes time and puts the patient through a poor experience. Our product is a patent pending, zero-prep, easy to wear headset with dry electrodes backed by a digital platform that offers instant upload and tools for analysis.
We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory for people with these debilitating diseases.
ANEUROTECH is developing its late stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies.
This established drug acts uniquely as a combined High Selective Serotonin 2A / Dopamine 4 receptor (5-HT2A/D4DR) Blocker in the brain. This to improve overall Antidepressant Treatment Response Rate and Treatment Durability in Partially Responsive Depression (PRD).
At ATENTIV Health, we know what it is like for children to struggle with ADHD. Through no fault of their own, their development of certain cognitive skills limit their ability to accomplish their goals. Their thoughts are scattered, and they have a hard time controlling their attention, impulsivity and self-control.
It is for this reason we discovered, developed and now provide clinically validated digital therapeutics that can effectively and safely treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children. In addition, all our treatments…
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease- modifying treatments for brain-related diseases and disorders.
At Bioasis, we undertake this challenge by focusing on a single goal: revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. Bioasis has developed and is commercializing our proprietary brain delivery technology, the xB3 platform, to make life-saving drugs brain-penetrant and deliver those therapies at a therapeutically relevant dose. Bioasis is dedicated to delivering hope to patients suffering with neurological diseases and disorders. Our breakthrough science focuses on transporting medicines across the blood- brain barrier, providing a path to hundreds of previously untreatable diseases of the central nervous system.
Brainstorm Cell Therapeutics is a leader in the development of innovative, autologous stem cell therapies for ALS, progressive MS, and other highly debilitating neurodegenerative diseases such as Parkinson’s Disease, Huntington’s Disease and Autism. The company’s innovative cell therapy platform uses patient’s own bone-marrow derived mesenchymal stem cells and modifies the cells to deliver high levels of neuronal repair and immunomodulatory molecules directly into the neurodegenerative disease cellular environment to effectively modify known disease pathways. Brainstorm has fully enrolled a phase 3 clinical trial for ALS at 6 US sites in October 2019 and expects top line clinical trial data in October 2020. Brainstorm is also actively enrolling participants in a US phase 2 clinical trial in progressive MS.
Cerecin is a US-Singapore headquartered biopharmaceutical company focused on neurology and brain health. The lead compound, CER-001 (Tricaprilin), is entering a global Phase 3 for Alzheimer's disease which will be focused in China. CER-001 is a small molecule structure lipid that addresses the metabolic deficit in Alzheimer’s disease by providing an alternative energy substrate to neurons. Cerecin’s pipeline includes Parkinson's disease, Migraine and Epilepsy. The company is also in-licensing new development stage CNS assets for development globally and in Asia-Pacific. Cerecin’s experienced management team have strong global CNS drug development capabilities with particular strengths in the US and China. Cerecin is supported by two major shareholders, Nestle and Wilmar (Yihai Kerry) groups.
Cognition Therapeutics is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina.
Cognition's proprietary lead product candidate, CT1812, is an orally delivered, small molecule designed to penetrate the blood-brain barrier and bind selectively to the σ-2 receptor complex which is present on synapses and acts as a key regulator of cellular damage and stress response. CT1812 clinical trials have demonstrated the products ability to displace and prevent oligomers from binding to the neurons and clears them into the CSF. CT1812 appears to prevent synaptotoxicity and facilitates the restoration of neuronal function.
Herantis is a CNS focused biotech company with a compelling portfolio of disease modifying assets Cerebral Dopamine Neurotrophic Factor CDNF and xCDNF. Both assets powerfully impact a core system in the body called Proteostasis, a key biological system which goes wrong in many neurodegenerative diseases. Both assets have demonstrated promising potential to significantly improve neuronal survival and thus slow or stop the progression of Parkinson’s and other neurodegenerative diseases.
Minoryx is developing leriglitazone, a brain penetrant PPAR gamma agonist with the potential to become the first to market treatment for AMN, the most prevalent form of X-ALD. The company is under conversations with regulatory authorities about an approval path based on data from its completed registration phase 2/3 study. Additionally, leriglitazone also showed strong potential for the treatment of Friedreich's Ataxia (phase 2 completed) and other orphan CNS disorders.
NervGen Pharma Corp. operates as a biotech company. The Company develops drugs for the treatment of spinal cord injury, multiple sclerosis, alzheimer, nerve damage, and neurodegenerative diseases. NervGen Pharma serves clients in Canada.
NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.
NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence.
Our initial focus is on myasthenia gravis, spinal muscular atrophy, Charcot-Marie Tooth’s disease, and sarcopenia. Each of these diseases has a profound impact on patient's functional level and their overall quality of life.
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other genetically validated neurodegenerative diseases with next-generation precision medicines. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients.
Revive Pharmaceuticals, Inc. [CSE: RVV, US: RVVTF]
Revive Therapeutics’ cannabinoid pharmaceutical portfolio focuses on rare inflammatory areas such as liver disease. The Company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantation. With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions. Sunovion’s track record of discovery, development and commercialization of important therapies has included Brovana® (arformoterol tartrate), Latuda® (lurasidone HCI), Aptiom® (eslicarbazepine acetate) Lonhala® Magnair® (glycopyrrolate), and, most recently, KYNMOBI® (apomorphine HCI) sublingual film.
Headquartered in Marlborough, MA Sunovion is an indirect, wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Canada, Inc., based in Mississauga, Ontario, is a wholly-owned direct subsidiary of Sunovion Pharmaceuticals Inc. Find more information at www.sunovion.com and connect on Twitter and Facebook @Sunovion.
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted, novel regenerative therapeutics for neurodegenerative diseases and developmental disorders. Our experience and passion for novel drug therapies have enabled us to develop a pipeline that includes synaptogenic treatment approaches for serious and difficult-to-treat diseases such as Alzheimer’s disease, Fragile X Syndrome, MS, Parkinsons, Traumatic Brain Injury, Stroke, and Autism Spectrum Disorders. Discovering restorative, novel therapeutics for patients with life altering neurodegenerative diseases and developmental disorders. -Clinically meaningful restoration of cognitive function -Regeneration of cerebral connections -Two Phase II pilot study trials completed -Biomarkers track cognitive improvement -Extensive toxicity safety profile -Partnerships with National Cancer Institute, National Institute of Health, and National Institute of Aging.
Unlearn is the only company creating Twintelligent RCTs™, which combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient trials. Twintelligent RCTs™ incorporate prognostic information from Digital Twins into randomized controlled trials to enable smaller control groups and generate evidence suitable for supporting regulatory decisions.
Vallon Pharmaceuticals (Nasdaq: VLON) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection.
Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine.
AlgoTherapeutix develops innovative solutions for complex pain.
AlgoTx's lead program is ATX01, a topical treatment for Chemotherapy-Induced Peripheral Neuropathy and other forms of peripheral neuropathic pain. ATX01 completed Phase I in late 2021 and is ready to enter a pivotal CIPN Phase II trial in Europe and the US.
AlgoTx raised 15 M€ in early funding including a Series A led by Bpifrance an Omnes Capital in 2020, and is currently raising a 20 M€ Series B to fund its Phase II development plan.
Altoida is creating a new gold standard in brain health with Precision Neurology. We're radically transforming the method for measuring brain function and diagnosing neurological disease, using just your smartphone or tablet.
Our products are backed by more than 20 years of innovative research in digital biomarkers, augmented reality (AR), and artificial intelligence (AI).
Altoida received FDA Breakthrough Device Designation in July 2021. Our first device is a Computerized Cognitive Assessment Aid that is classified as Class II, 510(k) exempt.
EpiVario is a preclinical stage biotechnology company focusing on neuropsychiatric disorders. Our co-founders, Dr. Shelley Berger and Dr. Philipp Mews, are leaders in the field of neuroepigenetics. They identified a key metabolic enzyme that functions within the nucleus of neurons to activate genes critical for long term memory. This epigenetic mechanism plays a critical role in consolidating trauma-induced fear and stress responses and drug craving associated with addiction. Thus, providing a new target for treating memory-related neuropsychiatric disorders, such as PTSD and drug and alcohol addiction, and starting with nicotine addiction.
We build and apply our AI driven tech platform to create the drugs of the future.
Our synergistic small molecule drug pipelines are either target-centric or disease-centric, or organ-centric. We pursue for example highly selective protein kinase inhibitors or protease inhibitors that are pivotal for a wide range of diseases and conditions. We focus on small molecule drugs that we design to select targets with high potency and outstanding selectivity in difficult-to-reach tissues. Our BRAINstorm™ and EYEdeal™ technologies provide the key data to overcome the blood-brain-barrier and tear film that prevents most other drugs from reaching their target organ.
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of people with serious neurological disorders such as stroke and amyotrophic lateral sclerosis (ALS). With offices in Boston (U.S.) and Paris (France), PathMaker is collaborating with world-class institutions to rapidly bring to market disruptive products for treating brain and other neurological disorders with high unmet medical need. More than 48 million people in the U.S., Europe and Asia suffer profound disabilities due to stroke, ALS, spinal cord injury, multiple sclerosis, traumatic brain injury, cerebral palsy and other related neurological disorders.
Our company's MyoRegulator® product is expected to be the world’s first non-invasive neuromodulation device to treat muscle spasticity, enabling treatment without the need for drugs or surgery. MyoRegulator® is based on PathMaker’s proprietary DoubleStim® technology for suppression of hyperexcitable spinal motor neurons. MyoRegulator® has been designated by the US Food and Drug Administration (FDA) as a “breakthrough medical device.” MyoRegulator® is an investigational medical device and is limited by Federal law to investigational use only. At PathMaker, we are opening up a new era of non-invasive therapy that promises to restore mobility and function in people with serious neurological disorders.
Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage. Sense is developing non-invasive brain scanners to enable: 1) Continuous, real-time brain injury monitoring in a hospital setting, and 2) Rapid and objective detection of traumatic brain injury and important stroke subtypes in a pre-hospital field environment such as an ambulance or battlefield.
Sense’s medical co-founders are experts in emergency medicine, neurology and neurocritical care seeking to eliminate the delays to time-sensitive treatment that can mean the difference between recovery, and disability or even death. Sense is developing noninvasive brain scanners which use low-pulse tailored radio frequency (RF) to scan the cranial vault in seconds. Healthy brain tissue, hemorrhagic tissue and ischemic tissue alter the signal in distinctly different ways. A proprietary algorithm classifies the stroke by subtype in field devices and detects signals which may indicate expanding hemorrhage in continuous monitoring devices.
Sense’s NeuSTAT continuous monitoring device is currently in a pivotal trial at multiple US sites, with plans to expand to Canada and India later in 2021. Sense’s NeuroHawk EMS, a triage device for civilian ambulance use is expected to begin a pivotal trial in 2022. A third device, the NeuroHawk is being developed with a military contract for detection and monitoring of traumatic brain injury (TBI) in a military field environment.